Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PPID | Q08752 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3524375 | 0.85 | EGLN3 (0.57) | EGLN3EGLN1 | |
| SCHEMBL3522685 | 0.81 | GAA (0.44) | HPGDHSD17B10ALDH1A1KDM4EGAA | |
| SCHEMBL3519390 | 0.76 | EGLN3 (0.69) | EGLN3EGLN1 | |
| SCHEMBL3760876 | 0.75 | EGLN3 (0.54) | HPGDHSD17B10ALDH1A1EGLN3KDM4E | |
| SCHEMBL3519951 | 0.74 | BACE1 (0.47) | HPGDHSD17B10ALDH1A1KDM4ELMNA | |
| SCHEMBL3517992 | 0.74 | ALDH1A1 (0.49) | HPGDHSD17B10ALDH1A1EGLN3KDM4E | |
| SCHEMBL3518478 | 0.74 | EGLN3 (0.50) | HPGDHSD17B10ALDH1A1EGLN3KDM4E | |
| SCHEMBL3756784 | 0.74 | NPC1 (0.48) | HPGDHSD17B10ALDH1A1EGLN3KDM4E | |
| SCHEMBL3524259 | 0.74 | EGLN3 (0.52) | HPGDHSD17B10ALDH1A1EGLN3KDM4E | |
| SCHEMBL3518821 | 0.74 | EGLN3 (0.49) | HPGDHSD17B10ALDH1A1EGLN3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101983384-A | Prolyl hydroxylase inhibitors | SMITHKLINE BEECHAM CORP | 2011-03-02 | — | — | CN | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| EP-2227770-A2 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009073497-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | HPGD 51/4885HSD17B10 613/4885ALDH1A1 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.